Medline Inc. announces launch of secondary offering of Class A common stock

Rhea-AI Summary

Medline (Nasdaq: MDLN) announced that certain selling stockholders affiliated with Blackstone, Carlyle, Hellman & Friedman and a subsidiary of Abu Dhabi Investment Authority have commenced an underwritten public offering of 75,000,000 shares of Class A common stock on March 3, 2026.

Underwriters have a 30-day option to purchase up to an additional 11,250,000 shares. Medline will not sell shares and will not receive any proceeds from this offering.

Positive

• Large offering size: 75,000,000 Class A shares could improve market liquidity
• Upsize option: underwriters may buy up to 11,250,000 additional shares, aiding orderly distribution
• Established banks leading the deal: Goldman Sachs, Morgan Stanley, BofA, J.P. Morgan

Negative

• Shares sold by holders: 75,000,000 offered by selling stockholders may create near-term selling pressure
• Medline receives no proceeds: company will not benefit financially from the offering
• Potential float increase: up to 86,250,000 shares could enter market if option exercised

Key Figures

Secondary shares offered: 75,000,000 shares Underwriter option: 11,250,000 shares Option period: 30 days +5 more

8 metrics

Secondary shares offered 75,000,000 shares Selling stockholders’ underwritten public offering

Underwriter option 11,250,000 shares Additional Class A shares over 30-day option period

Option period 30 days Underwriters’ option to purchase additional shares

Shares registered for resale 75,000,000 shares S-1 secondary offering registration by selling stockholders

Additional shares under S-1 option 11,250,000 shares Underwriters’ additional purchase option in S-1

Class A shares outstanding 811,647,534 shares As of February 23, 2026 per S-1

2025 net sales $28.4 billion Full-year 2025 per S-1 filing

2025 net income $1.2 billion Full-year 2025 per S-1 filing

Market Reality Check

Price: $45.85 Vol: Volume 2,039,534 is below...

normal vol

$45.85 Last Close

Volume Volume 2,039,534 is below 20-day average 2,779,842 (relative volume 0.73). normal

Technical Price $45.85 is trading above 200-day MA at $44.38 and about 9.88% below the 52-week high.

Peers on Argus

No peer stocks in the provided sector list showed momentum flags, suggesting MDL...

No peer stocks in the provided sector list showed momentum flags, suggesting MDLN’s -3.49% move was driven by company-specific news about the secondary offering rather than a sector-wide move.

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Earnings report	Positive	-3.6%	Reported strong 2025 sales and guidance despite weaker margins and income.
Feb 18	Conference participation	Neutral	+3.4%	Announced CEO and CFO presentation at major Barclays healthcare conference.
Jan 28	Earnings date set	Neutral	-4.3%	Scheduled Q4 and full-year 2025 earnings release and webcast date.
Dec 30	Conference participation	Neutral	+0.2%	Announced J.P. Morgan 2026 Healthcare Conference presentation and webcast.
Dec 18	IPO and option	Positive	+5.4%	Closed upsized IPO with full exercise of underwriters’ option at $29.00.

Pattern Detected

Recent news often triggered sizable single-day moves, with one prior offering-related event seeing a positive reaction while strong fundamental updates have sometimes been sold.

Recent Company History

Over the last few months Medline has moved through its IPO and first public-company milestones. The upsized IPO closing on Dec 18, 2025 with a +5.44% reaction contrasts with the -3.62% move after strong yet margin-pressured 2025 results on Feb 25, 2026. Conference participation headlines produced mixed but modest reactions. Today’s secondary offering by existing holders follows that IPO, adding another liquidity event against a backdrop of solid sales growth but sensitive post-earnings trading.

Market Pulse Summary

This announcement details a sizable secondary sale of 75,000,000 Medline Class A shares, plus a 11,2...

Analysis

This announcement details a sizable secondary sale of 75,000,000 Medline Class A shares, plus a 11,250,000-share underwriter option, by major existing stockholders. Medline will not receive proceeds, so the event mainly affects ownership mix and tradable float rather than the balance sheet. In context of strong 2025 net sales of $28.4 billion and a recent IPO, investors may focus on sponsor exit pacing, overall share count of 811,647,534, and future earnings execution as key metrics to monitor.

Key Terms

underwritten public offering, registration statement, Securities and Exchange Commission, prospectus, +1 more

5 terms

underwritten public offering financial

"have commenced an underwritten public offering of 75,000,000 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

registration statement regulatory

"pursuant to a registration statement filed with the Securities and Exchange Commission"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

Securities and Exchange Commission regulatory

"filed with the Securities and Exchange Commission (the “SEC”)"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

prospectus regulatory

"The proposed offering of these securities will be made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

Class A common stock financial

"shares of Medline’s Class A common stock pursuant to a registration statement"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

AI-generated analysis. Not financial advice.

NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) have commenced an underwritten public offering of 75,000,000 shares of Medline’s Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline’s Class A common stock.

Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers, and Blackstone Capital Markets and Carlyle are acting as co-managers for the proposed offering.

The proposed offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
  
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar words or phrases that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements. These forward-looking statements relate to matters such as our industry, business strategy, costs, and costs savings, impacts of accounting standards and guidance, goals and expectations, market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources, legal matters, trends, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainty, and changes in circumstances, many of which are beyond our control, that could cause actual results to differ materially.

Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

Contacts:
Investor Relations:
Karen King
Global Head Investor Relations

Patrick Flaherty
Director, Investor Relations

(847) 247-7222
IR@medline.com

Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
media@medline.com

Source: Medline Inc.

FAQ

What did Medline (MDLN) announce on March 3, 2026 about a secondary offering?

Medline announced a selling-stockholder underwritten offering of 75,000,000 Class A shares. According to the company, underwriters have a 30-day option to buy an additional 11,250,000 shares, and Medline will not receive proceeds.

Will Medline (MDLN) receive money from the March 3, 2026 offering?

No, Medline will not receive any proceeds from this offering. According to the company, the shares are being sold by selling stockholders, not by Medline itself.

Who are the underwriters for the MDLN March 3, 2026 offering and what roles do they play?

Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are global coordinators and joint bookrunners. According to the company, Blackstone Capital Markets and Carlyle serve as co-managers for the proposed offering.

How many additional shares can underwriters purchase for the MDLN offering and within what timeframe?

Underwriters can buy up to 11,250,000 additional Class A shares within a 30-day option period. According to the company, this overallotment option supports potential stabilization during distribution.

Does the March 3, 2026 MDLN press release mean shares can be sold immediately?

No, the securities cannot be sold or offers accepted until the registration statement is effective. According to the company, sales are subject to SEC registration becoming effective and prospectus availability.